Dr Jacques-Eric GottenbergRhumatologue à Strasbourg

2026Rheumatology (Oxford, England)PubMed

A specific molecular profiling of secreted rheumatoid factors in Sjögren' s disease patients with lymphoma

2026Arthritis & rheumatology (Hoboken, N.J.)PubMed

Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression

2026Annals of the rheumatic diseasesPubMed

A genetic variant of BAFF is associated with the risk of lymphoma in Sjögren disease

2026NPJ systems biology and applicationsPubMed

The SjD Map: an interactive pathway tour into Sjögren's disease signalling mechanisms

2026Expert review of clinical immunologyPubMed

Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS study

2025Rheumatology and therapyPubMed

Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren's Disease and Association with Patient-Reported Outcomes

2025Lancet (London, England)PubMed

Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Deep Immunophenotyping and Clustering Identifies Biomarkers Predictive of Lymphoma in Primary Sjögren Disease

2025JAMA dermatologyPubMed

Cutaneous Vasculitis in Primary Sjögren Disease

2025Annals of the rheumatic diseasesPubMed

Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)

2025Nature reviews. RheumatologyPubMed

2023 International Rome consensus for the nomenclature of Sjögren disease

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data

2025RMD openPubMed

Impact of Sjögren's disease on quality of sexual life using the Qualisex score

2024RMD openPubMed

Stability of symptom-based subtypes in Sjogren's disease

2024RMD openPubMed

Development of a web-based ecological momentary assessment tool to measure day-to-day variability of the symptoms in patients with Sjögren's disease

2024The Lancet. RheumatologyPubMed

Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study

2024RMD openPubMed

Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease

2026ACR open rheumatologyPubMed

FADD Protein for the Early Diagnosis of Rheumatoid Arthritis

2026Joint bone spinePubMed

Baseline characteristics of the TRANSLATE2 cohort: A prospective study on rheumatoid arthritis-associated interstitial lung disease

2025The Lancet. RheumatologyPubMed

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial

2025Joint bone spinePubMed

Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE

2026Joint bone spinePubMed

Prescription of targeted therapies in patient with a history of cancer

2026Rheumatology (Oxford, England)PubMed

Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort

2025Annals of the rheumatic diseasesPubMed

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland

2025Annals of the rheumatic diseasesPubMed

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

2025Joint bone spinePubMed

Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE

2025BMJ openPubMed

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

2024Rheumatology and therapyPubMed

Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study

2025RMD openPubMed

Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study

2024RMD openPubMed

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

2024Annals of the rheumatic diseasesPubMed

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

2025Autoimmunity reviewsPubMed

Combination targeted therapy with two biologic/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy

2025Annals of the rheumatic diseasesPubMed

Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer

2025Advances in therapyPubMed

Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals

2026Autophagy reportsPubMed

LC3-associated phagocytosis is impaired in monocyte-derived macrophages from systemic sclerosis patients

2026Rheumatology (Oxford, England)PubMed

Suspected ICANS in systemic sclerosis: think twice before corticosteroids

2026Annals of the rheumatic diseasesPubMed

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series

2026Human vaccines & immunotherapeuticsPubMed

Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials

2025BMC medical educationPubMed

Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture

2025RMD openPubMed

Novel vascular damage markers in SLE: insights from carotid colour Doppler ultrasound and aortic oscillometry in the LUPCARD cohort

2024CellsPubMed

Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients

2026Rheumatology (Oxford, England)PubMed

Acute myocarditis after switching between two adalimumab biosimilars

2026Human vaccines & immunotherapeuticsPubMed

Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials

2025The Lancet. RheumatologyPubMed

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial

2025Advances in therapyPubMed

Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals

2025Autoimmunity reviewsPubMed

Combination targeted therapy with two biologic/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

2025Joint bone spinePubMed

French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases

2025Annals of the rheumatic diseasesPubMed

Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer

2026Arthritis & rheumatology (Hoboken, N.J.)PubMed

Clinical Images: Sarcoidosis revealed by recurrent dactylitis

2026Rheumatology (Oxford, England)PubMed

Time and patient journey to axial spondyloarthritis diagnosis: a retrospective study in French primary care

2025JAMA dermatologyPubMed

Cutaneous Vasculitis in Primary Sjögren Disease

2023 · doctorant : Renaud Felten

Identification de nouvelles cibles thérapeutiques au cours du syndrome de Gougerot-Sjögren primitif (SJp)

2013 · doctorant : Antoine François

Rôle du ''B-cell activating factor'' (BAFF) et des lymphocites B dans la fibrose pulmonaire et cutanée dans la sclérodermie systémique

2013 · doctorant : Ya-Zhuo Gong

Role of salivary gland epithelial cells in the differentiation and activation of T lymphocytes in primary Sjögren's syndrome

— · doctorant : Clémentine Pouenat

L'inhibition du récepteur FcRn dans la maladie de Sjögren

— · doctorant : Wenxin Ou

Le rôle de CD180 dans l’activation des cellules B et la pathogenèse du syndrome de Sjögren